Pharmacological effects of saw palmetto extract in the lower urinary tract
Authors:
Open Access
- 5 March 2009
- journal article
- review article
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 30 (3) , 271-281
Abstract
Saw palmetto extract (SPE), an extract from the ripe berries of the American dwarf palm, has been widely used as a therapeutic remedy for urinary dysfunction due to benign prostatic hyperplasia (BPH) in Europe. Numerous mechanisms of action have been proposed for SPE, including the inhibition of 5α-reductase. Today, α1-adrenoceptor antagonists and muscarinic cholinoceptor antagonists are commonly used in the treatment of men with voiding symptoms secondary to BPH. The improvement of voiding symptoms in patients taking SPE may arise from its binding to pharmacologically relevant receptors in the lower urinary tract, such as α1-adrenoceptors, muscarinic cholinoceptors, 1,4-dihyropyridine receptors and vanilloid receptors. Furthermore, oral administration of SPE has been shown to attenuate the up-regulation of α1-adrenoceptors in the rat prostate induced by testosterone. Thus, SPE at clinically relevant doses may exert a direct effect on the pharmacological receptors in the lower urinary tract, thereby improving urinary dysfunction in patients with BPH and an overactive bladder. SPE does not have interactions with co-administered drugs or serious adverse events in blood biochemical parameters, suggestive of its relative safety, even with long-term intake. Clinical trials (placebo-controlled and active-controlled trials) of SPE conducted in men with BPH were also reviewed. This review should contribute to the understanding of the pharmacological effects of SPE in the treatment of patients with BPH and associated lower urinary tract symptoms (LUTS).Keywords
This publication has 73 references indexed in Scilit:
- Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extractProstate Cancer and Prostatic Diseases, 2004
- Ginkgo biloba extract modifies hypoglycemic action of tolbutamide via hepatic cytochrome P450 mediated mechanism in aged ratsLife Sciences, 2004
- Evaluation of the Clinical Benefit of Permixon and Tamsulosin in Severe BPH Patients—PERMAL Study Subset AnalysisEuropean Urology, 2004
- Immune response in hormonally-induced prostatic hyperplasia in the dogVeterinary Immunology and Immunopathology, 2001
- Interactions Between Herbal Medicines and Prescribed DrugsDrugs, 2001
- Cell Kinetic in Epithelium and Stroma of Benign Prostatic HyperplasiaJournal of Urology, 1997
- Effects of the Sabal serrulata extract IDS 89 and its subfractions on 5α-reductase activity in human benign prostatic hyperplasiaThe Prostate, 1996
- Placebo-Controlled Evaluation of the Efficacy and Tolerability of Permixon® in Benign Prostatic Hyperplasia after Exclusion of Placebo RespondersClinical Drug Investigation, 1995
- Binding of permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostateJournal of Steroid Biochemistry, 1984
- Inhibition of androgen metabolism and binding by a liposterolic extract of “serenoa repens B” in human foreskin fibroblastsJournal of Steroid Biochemistry, 1984